PLAT and hemorrhage: However, until now, no treatment strategy has proved to be effective by controlled clinical trials, except for the only Food and Drug Administration (FDA) approved recombinant tissue plasminogen activator (tPA), which acts through vascular recanalization and tends to have numerous limitations, of which, the transformation from ischemia to hemorrhage and narrow therapeutic window are the most prominent ones [2].